Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
about
Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacyIncreased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitusFixed combination of losartan and hydrochlorothiazide and reduction of risk of strokeComparing angiotensin II receptor blockers on benefits beyond blood pressureLeft ventricular hypertrophy: The relationship between the electrocardiogram and cardiovascular magnetic resonance imaging.Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study.A comparison of Cornell and Sokolow-Lyon electrocardiographic criteria for left ventricular hypertrophy in a military male population in Taiwan: the Cardiorespiratory fitness and HospItalization Events in armed Forces study.Prevalence and determinants of left ventricular hypertrophy in hypertensive patients at a primary care clinicThe left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy.Impact of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers on mortality of coronary artery bypass grafting.LIFE and SCOPE: what guidance do they offer alongside ALLHAT and ANBP2?Hypertension treatment and stroke prevention.Hypertensive heart disease: effects of lifestyle modifications and antihypertensive drug treatment.The implications of a growing evidence base for drug use in elderly patients Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients.Angiotensin II receptor blockers in older patients.Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.Ablation of idiopathic right ventricular outflow tract tachycardia: current perspectives.A comparison of cornell and sokolow-lyon electrocardiographic criteria for left ventricular hypertrophy in korean patientsRole of angiotensin II in the evolution of diastolic heart failure.The renin-angiotensin system and right ventricular structure and function: The MESA-Right Ventricle Study.Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy.Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT).Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials.Left ventricular hypertrophy and clinical outcomes in hypertensive patients.Left ventricular hypertrophy may be transient in the emergency department.Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.Role of nuclear unphosphorylated STAT3 in angiotensin II type 1 receptor-induced cardiac hypertrophy.A role for single-pill triple therapy in hypertension.Losartan in cardiovascular disease.Hypertension and Diabetes: what are the pros to treating early surrogates?Northern Shanghai Study: cardiovascular risk and its associated factors in the Chinese elderly-a study protocol of a prospective study design.Drug therapy for resistant hypertension: simplifying the approach.Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?Angiotensin receptor blockers: pharmacology, efficacy, and safety.Medical treatment of hypertension in patients with heart failure with preserved ejection fraction.Angiotensin II receptor antagonists in acute coronary syndromes.Hypertension as a risk factor for heart failure.Prognostic factors of clinical endpoints in elderly patients with atrial fibrillation during a 2-year follow-up in China: An observational cohort study.Electrocardiographic left ventricular hypertrophy predicts atrial fibrillation independent of left ventricular mass.Atrial Dilatation Development in Hypertensive Treated Patients: The Campania-Salute Network.
P2860
Q24652838-F3E415FE-CB3A-4A41-855F-8059A87AA7C0Q24806075-0921BF36-AFA2-47AA-B746-E3C660F3E4FCQ28219593-CA5E5418-CCE5-41CC-83C6-4614A546ECDEQ30360678-1236557C-14F7-4359-9400-54E0B51A9730Q30867239-8310F12A-98C0-499E-A6A2-918526AB9760Q31149033-181BC2A6-BE53-4C15-9C03-52AA790669F0Q33714661-A470B23A-85D3-4ED6-B4D0-3C3383B51C16Q34220918-DF8572FB-C693-4AB1-BB02-88E938688F58Q34915626-050BD37C-645D-4D1D-85B7-827E8ACFE9F9Q35617259-3A1DDA26-3468-4BD6-8148-A4E6C5BE3A95Q35636620-F30A4FC5-254C-4042-B07A-55AC46C8262BQ35649169-B2CDD9DA-2BBE-4A95-8FD7-F1BDF88A1A12Q35821934-637BA45C-BE78-4E5B-B861-7430ED807523Q35827554-FEEB7C1D-3896-40DF-B9D3-3D0565DBAB9CQ35843149-8BF7B3A1-B08F-4E34-AB3B-182CE955B3C9Q35925533-848F2D76-6CC9-4BCF-9360-D5F961AF6EFCQ36247412-6E159190-08B4-4CDB-B456-D841F5F750ABQ36306749-694FF7C0-EB68-4A21-92FB-715A016492D6Q36332211-608724AF-CD78-4249-8929-2209470B0773Q36366106-849FE56C-1CAD-4A22-8920-8D92DB9261A8Q36540314-09D8A67B-A0A7-49C5-9EE8-458E3CD7474CQ36807421-A49D55B8-9E76-409A-97B2-06C9A17D5761Q36815965-FA0CFBB7-09E1-4815-8C64-CDA6A0122D92Q37147735-D3E1BCB7-99E5-4566-AFDB-8F1E798421E4Q37311317-095E83A9-B60D-4C6B-9AB0-E5C7446ED6B7Q37359616-8A6B2A91-F6AD-4D1F-9F68-253010D0CA94Q37467862-9E5C3271-0D6A-42F8-A43D-283112873800Q37483049-E53D7A03-F4AF-4D27-B187-9A34EC3C7E5BQ37608510-2EEF3376-6A40-4E0B-B781-A34BE9824C8CQ37624284-5F283F50-D5C6-4831-8ABF-8FCD5DDE8A1BQ37728214-C437733E-6832-48E0-8912-9E1E03619454Q37832774-ABA17AE0-3ED0-40FE-B871-6C9CE21533C9Q37892908-2DE26E0E-DE5B-424F-907E-C69A4B93D32DQ37928133-3577197C-C6C3-41C4-8465-2653C2409BD3Q38155804-104058E9-EAE2-4A99-9D58-E0A3979E2A3AQ38167346-4BFCD6DD-8AC1-4FD4-B619-CA4FB0E6376AQ38208967-D11FD6A9-D3C6-4CA8-A454-A16A21DC2D6BQ38620315-17187C3E-8E47-4420-958C-4B707DCDF7D6Q39064464-23A70B58-2A38-4C72-85D1-09A29C888F57Q39773724-408F2922-9A3C-4686-8E63-5D7DB87FF3FF
P2860
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Regression of electrocardiogra ...... in Hypertension (LIFE) Study.
@en
Regression of electrocardiogra ...... oint reduction in Hypertension
@nl
type
label
Regression of electrocardiogra ...... in Hypertension (LIFE) Study.
@en
Regression of electrocardiogra ...... oint reduction in Hypertension
@nl
prefLabel
Regression of electrocardiogra ...... in Hypertension (LIFE) Study.
@en
Regression of electrocardiogra ...... oint reduction in Hypertension
@nl
P2093
P1433
P1476
Regression of electrocardiogra ...... in Hypertension (LIFE) Study.
@en
P2093
Bjorn Dahlof
Jonathan M Edelman
Katherine E Harris
Losartan Intervention for Endpoint reduction in hypertension Study Investigations
Markku S Nieminen
Peter Aurup
Peter M Okin
Steven Snapinn
Stevo Julius
Sverker Jern
P304
P356
10.1161/01.CIR.0000083724.28630.C3
P407
P577
2003-07-28T00:00:00Z